Home
Haystack Oncology, Inc.

Haystack Oncology, Inc. Market Share Analysis for May 2026

Industry: N/A

Domainhaystackoncology.com

Year Founded2021

Employees51 - 200

Annual Revenue$2M - $5M

Haystack Oncology, Inc.

Haystack Oncology, Inc. (including company regionals)

haystackoncology.com

See more website traffic and engagement information

Haystack Oncology, Inc. Revenue up to May 2026 is 2M - 5M

revenue generated by Haystack Oncology, Inc. top domains

Haystack Oncology, Inc. top domains revenue over 3 years

Revenue for Haystack Oncology, Inc. top domains

haystackoncology.com2M - 5M

See more with Sales Intelligence

Total visits to Haystack Oncology, Inc.'s top domains

Understand Haystack Oncology, Inc. market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Haystack Oncology, Inc.'s top domains

Analyze Haystack Oncology, Inc. engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Haystack Oncology, Inc.'s top domains

See how Haystack Oncology, Inc. keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Haystack Oncology, Inc. top competitors by domain

Looks like there’s not enough data here

No Data to Display

Top technologies used by Haystack Oncology, Inc.

These are the website technologies, by industry, used by Haystack Oncology, Inc. top domains

Content Management System (4)

WordPress

Email Services (3)

Sendgrid

Marketing (3)

Google Marketing Platform

Mobile (3)

Meta Viewport

More Technologies

10

See all

News & Signals from Haystack Oncology, Inc.

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsHaystackoncology partnered with TriSalus Life Sciences, Inc. on Dec 26th '23.Baltimore-based Haystack Oncology, a Quest Diagnostics company and developer of personalized MRD technology, has entered a research collaboration with TriSalus Life Sciences to evaluate therapeutic response and provide molecular insights in connection with the clinical development of TriSalus' SD-101, an investigational class C toll-like receptor-9 (TLR9) agonist.

NewsHaystackoncology partnered with The Cancer Institute of New Jersey on Nov 18th '23.Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, has entered into a collaboration with Rutgers Cancer Institute of New Jersey to use Haystack Oncology's industry-leading personalized MRD technology (Haystack MRD(TM) to help evaluate therapeutic response and provide molecular insights for a Rutgers Cancer Institute clinical trial examining early-stage triple-negative breast cancer (TNBC) patients undergoing treatment in the adjuvant setting with liposomal doxorubicin and carboplatin.

NewsHaystackoncology expands offices to United Kingdom, Northern Europe, Europe.Haystack Oncology plans to relocate its workforce to the 135,000 square foot building at 101 W. Dickman Street and part of the mixed-use Baltimore Peninsula, in late 2023.